Clinical Trials Browser

Has results × Breast Neoplasms × pembrolizumab × Clear all

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT03237572 2026-02-09

Breast-48

Phase 1 Terminated

13 enrolled 10 charts

Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT02999477 2026-01-29

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Phase 1 Completed

32 enrolled 23 charts

Breast Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast Neoplasms

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Phase 2 Completed

76 enrolled 14 charts

Breast Neoplasms

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1/2 Completed

185 enrolled 23 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03106415 2025-06-27

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

23 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03222856 2025-06-05

KELLY

Phase 2 Completed

44 enrolled 17 charts

Breast Neoplasms

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03366844 2025-04-29

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Phase 1/2 Active not recruiting

66 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03632941 2025-03-12

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Phase 2 Active not recruiting

8 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02752685 2025-01-29

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Phase 2 Active not recruiting

70 enrolled 7 charts

Breast Neoplasms

NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Phase 1 Completed

20 enrolled 14 charts

Breast Neoplasms

NCT03514121 2024-11-22

FPA150-001

Phase EARLY_PHASE1 Terminated

95 enrolled 36 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Active not recruiting

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2 Completed

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02657889 2022-12-01

TOPACIO

Phase 1/2 Completed

122 enrolled 29 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02730130 2022-10-19

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

Phase 2 Completed

17 enrolled 10 charts

Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

Phase 1/2 Completed

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03197389 2021-05-19

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Phase EARLY_PHASE1 Completed

54 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03051672 2021-04-27

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

Phase 2 Terminated

8 enrolled 8 charts

Breast Neoplasms

NCT02447003 2020-12-16

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Phase 2 Completed

254 enrolled 22 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02395627 2020-07-07

Reversing Therapy Resistance With Epigenetic-Immune Modification

Phase 2 Terminated

38 enrolled 18 charts

Breast Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02129556 2019-02-15

PANACEA

Phase 1/2 Completed

58 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis